Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13501482 | 0.80 | CYP19A1 (0.43) | CYP19A1NPC1 | |
| SCHEMBL24854078 | 0.78 | LTB4R (0.39) | MAOBHTT | |
| SCHEMBL18812630 | 0.77 | CA2 (0.48) | CA2CA1AHRCYP19A1NPC1 | |
| SCHEMBL406202 | 0.77 | NISCH (0.44) | HTT | |
| SCHEMBL19565507 | 0.77 | NISCH (0.44) | HTT | |
| SCHEMBL12610431 | 0.77 | NISCH (0.44) | HTT | |
| SCHEMBL406079 | 0.75 | POLB (0.47) | L3MBTL1 | |
| SCHEMBL19002483 | 0.75 | HRH4 (0.48) | AHRNPC1 | |
| SCHEMBL1119149 | 0.75 | CA2 (0.49) | CA2CA1AHRCYP19A1NPC1 | |
| SCHEMBL1119152 | 0.75 | CA2 (0.49) | CA2CA1AHRCYP19A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247618-A1 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | JANSSEN PHARMACEUTICA, N.C. (BE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247618-A1 | PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES | CYP3A4, CYP3A5, CYP1A2 | CA2 3270/4885CA1 2909/4885AHR 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.